Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
04 2019
Historique:
received: 10 07 2018
accepted: 24 09 2018
revised: 19 09 2018
pubmed: 30 11 2018
medline: 10 8 2019
entrez: 30 11 2018
Statut: ppublish

Résumé

Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We have previously reported the genomic landscape of patients with CRLF2 rearrangements (CRLF2-r) using both whole genome and exome sequencing, which identified a number of potential clonal and sub-clonal genomic alterations. In this study, we aimed to assess when the CRLF2-r; IGH-CRLF2 or P2RY8-CRLF2, arose during the evolution of both Down syndrome-ALL (DS-ALL) and non-DS-ALL. Using fluorescence in situ hybridisation, we were able to track up to four structural variants in single cells from 47 CRLF2-r B-ALL patients, which in association with our multiplex single-cell analysis of a further four patients, permitted simultaneous tracking of copy number alterations, structural and single nucleotide variants within individual cells. We observed CRLF2-r arising as both early and late events in DS and non-DS-ALL patients. Parallel evolution of discrete clones was observed in the development of CRLF2-r B-ALL, either involving the CRLF2-r or one of the other tracked abnormalities. In-depth single-cell analysis identified both linear and branching evolution with early clones harbouring a multitude of abnormalities, including the CRLF2-r in DS-ALL patients.

Identifiants

pubmed: 30487598
doi: 10.1038/s41375-018-0297-4
pii: 10.1038/s41375-018-0297-4
pmc: PMC6398588
mid: EMS79778
doi:

Substances chimiques

CRLF2 protein, human 0
Receptors, Cytokine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

893-904

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 105104/Z/14/Z
Pays : United Kingdom

Références

Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26:123–35.
doi: 10.1016/j.blre.2012.01.001
Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499–503.
doi: 10.1016/S0140-6736(99)09403-9
Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102:2321–33.
doi: 10.1182/blood-2002-12-3817
Maia AT, van der Velden VHJ, Harrison CJ, Szczepanski T, Williams MD, Griffiths MJ, et al. Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia. 2003;17:2202–6.
doi: 10.1038/sj.leu.2403101
Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA. 2002;99:8242–7.
doi: 10.1073/pnas.112218799
Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia AfterTEL-AML1 gene fusion in utero. blood. 1999;94:1057–62.
Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34.
doi: 10.1016/S1470-2045(08)70339-5
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. New Engl J Med. 2009;360:470–80.
doi: 10.1056/NEJMoa0808253
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New Engl J Med. 2014;371:1005–15.
doi: 10.1056/NEJMoa1403088
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114:2688–98.
doi: 10.1182/blood-2009-03-208397
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41:1243–6.
doi: 10.1038/ng.469 pubmed: 2783810
Chapiro E, Russell L, Lainey E, Kaltenbach S, Ragu C, Della-Valle V, et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia. 2010;24:642–5.
doi: 10.1038/leu.2009.231
Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, et al. IGH@ Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2012;30:3100–8.
doi: 10.1200/JCO.2011.40.3907
Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49:1104–13.
doi: 10.1002/gcc.20818
Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26:2204–11.
doi: 10.1038/leu.2012.84
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22:153–66.
doi: 10.1016/j.ccr.2012.06.005 pubmed: 3422513
Morak M, Attarbaschi A, Fischer S, Nassimbeni C, Grausenburger R, Bastelberger S, et al. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2–harboring clones as main relapse-driving force in childhood ALL. Blood. 2012;120:5134–42.
doi: 10.1182/blood-2012-07-443218 pubmed: 4194314
Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci USA. 2017;114:E4030–E9.
doi: 10.1073/pnas.1702489114 pubmed: 28461505
Wolman SR. Cytogenetic heterogeneity: its role in tumor evolution. Cancer Genet Cytogenet. 1986;19:129–40.
doi: 10.1016/0165-4608(86)90380-8 pubmed: 3455660
Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–61.
doi: 10.1038/nature09650
Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.
doi: 10.1038/ncomms7604 pubmed: 4377644
Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014;46:116–25.
doi: 10.1038/ng.2874 pubmed: 3960636
Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, et al. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res. 2013;23:2115–25.
doi: 10.1101/gr.159913.113 pubmed: 3847780
Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.
doi: 10.1038/nature09807 pubmed: 4504184
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med. 2012;366:883–92.
doi: 10.1056/NEJMoa1113205
Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, et al. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes Chromosomes Canc. 2017;56:363–72.
doi: 10.1002/gcc.22439
le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008;14:47–58.
doi: 10.1016/j.ccr.2008.05.015 pubmed: 2572185
Jeffries SJ, Jones L, Harrison CJ, Russell LJ. IGH@ translocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2014;99:1334–42.
doi: 10.3324/haematol.2014.103820 pubmed: 4116832
Furness CL, Mansur MB, Weston VJ, Ermini L, van Delft FW, Jenkinson S, et al. The subclonal complexity of STIL-TAL1+T-cell acute lymphoblastic leukaemia. Leukemia. 2018;32:1984–1993.
doi: 10.1038/s41375-018-0046-8 pubmed: 6127084
De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, et al. Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia. 2018;321:358–1369.
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
doi: 10.1038/nature13038 pubmed: 4991939
Dussiau C, Fontenay M. Mechanisms underlying the heterogeneity of myelodysplastic syndromes. Exp Hematol. 2018;58:17–26.
doi: 10.1016/j.exphem.2017.10.004
Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. The clonal origins of leukemic progression of myelodysplasia. Leukemia. 2017;31:1928–35.
doi: 10.1038/leu.2017.17
Kent DG, Ortmann CA, Green AR. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:1865–6.
doi: 10.1056/NEJMc1503143
Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377–80.
doi: 10.1126/science.1164266 pubmed: 2746051
van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood. 2011;117:6247–54.
doi: 10.1182/blood-2010-10-314674
Ford AM, Mansur MB, Furness CL, van Delft FW, Okamura J, Suzuki T, et al. Protracted dormancy of pre-leukemic stem cells. Leukemia. 2015;29:2202–7.
doi: 10.1038/leu.2015.132 pubmed: 4564945
Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28:1705–15.
doi: 10.1038/leu.2014.13
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–33.
doi: 10.1038/ng.2891 pubmed: 4636053
Davies NJ, Kwok M, Gould C, Oldreive CE, Mao J, Parry H, et al. Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. Oncotarget. 2017;8:44749–60.
doi: 10.18632/oncotarget.17432 pubmed: 5546515
Belderbos ME, Koster T, Ausema B, Jacobs S, Sowdagar S, Zwart E, et al. Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding. Blood. 2017;129:3210–20.
doi: 10.1182/blood-2016-12-758250
Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011;118:1854–64.
doi: 10.1182/blood-2010-11-320309
Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47:257–62.
doi: 10.1038/ng.3202
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell . 2011;144:27–40.
doi: 10.1016/j.cell.2010.11.055 pubmed: 3065307
Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, et al. The butterfly effect in cancer: a single base mutation can remodel the cell. Proc Natl Acad Sci USA. 2015;112:1131–6.
doi: 10.1073/pnas.1424012112
Lee RS, Stewart C, Carter SL, Ambrogio L, Cibulskis K, Sougnez C, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122:2983–8.
doi: 10.1172/JCI64400 pubmed: 3408754
Cabelof DC, Patel HV, Chen Q, van Remmen H, Matherly LH, Ge Y, et al. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood. 2009;114:2753–63.
doi: 10.1182/blood-2008-11-190330 pubmed: 2756130
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010;115:1006-17.
doi: 10.1182/blood-2009-08-235408

Auteurs

N Potter (N)

The Institute of Cancer Research, London, UK.

L Jones (L)

Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

H Blair (H)

Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

S Strehl (S)

CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.

C J Harrison (CJ)

Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.

M Greaves (M)

The Institute of Cancer Research, London, UK.

L Kearney (L)

The Institute of Cancer Research, London, UK.

L J Russell (LJ)

Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK. lisa.russell@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH